BPC-157 vs Desmopressin
Overview
BPC-157 is primarily a healing & recovery peptide, while Desmopressin is used for hormonal.
This page compares BPC-157 and Desmopressin across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| BPC-157 | Desmopressin | |
|---|---|---|
| Category | Healing & Recovery | Hormonal |
| Regulatory status (US) | Compounding (Rx) — Apr 2026 | FDA approved |
| Typical dosage | 250-500 mcg | 0.1–0.8 mg/day oral (central DI); 0.3 mcg/kg IV (hemostasis, max 20 mcg); 0.2–0.6 mg at bedtime (nocturnal enuresis); 27.7–55.3 mcg sublingual (nocturia) |
| Frequency | daily | Once to twice daily (oral); single IV infusion or every 8–12 hours (hemostasis); once nightly (nocturia) |
| Reported benefits | Accelerated wound healing, tendon and ligament repair, gut health improvement, reduced inflammation, neuroprotective effects | central diabetes insipidus management, primary nocturnal enuresis in children, nocturia due to nocturnal polyuria, perioperative hemostasis in mild hemophilia A, hemostasis in Type I von Willebrand disease, management of polyuria following head trauma or pituitary surgery |
| Reported side effects | Generally well-tolerated. Rare: injection site reactions, mild fatigue | hyponatremia (boxed warning), headache, facial flushing, nausea, abdominal cramps, fluid retention, hypotension, reflex tachycardia, hypertension, tachyphylaxis with repeated dosing, rare anaphylaxis |
Key differences
Primary use. BPC-157 is categorised under Healing & Recovery, while Desmopressin falls under Hormonal. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. BPC-157: not FDA-approved; compounding permitted with a prescription as of April 2026. Desmopressin: FDA-approved.
Dosing. BPC-157 is typically dosed at 250-500 mcg (daily). Desmopressin is typically dosed at 0.1–0.8 mg/day oral (central DI); 0.3 mcg/kg IV (hemostasis, max 20 mcg); 0.2–0.6 mg at bedtime (nocturnal enuresis); 27.7–55.3 mcg sublingual (nocturia) (Once to twice daily (oral); single IV infusion or every 8–12 hours (hemostasis); once nightly (nocturia)).
Can you stack them?
Some protocols combine peptides, but stacking BPC-157 and Desmopressin has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between BPC-157 and Desmopressin?
- BPC-157 is primarily a healing & recovery peptide, while Desmopressin is used for hormonal. BPC-157 is not FDA-approved; compounding permitted with a prescription (as of April 2026), whereas Desmopressin is FDA-approved for one or more indications.
- What is BPC-157 used for?
- Healing & recovery, gut health.
- What is Desmopressin used for?
- Synthetic ADH analog (DDAVP) FDA-approved for diabetes insipidus, nocturnal enuresis, and bleeding disorders.
- Can you take BPC-157 and Desmopressin together?
- Some users combine peptides within a single protocol, but stacking BPC-157 and Desmopressin has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is BPC-157 or Desmopressin FDA-approved?
- BPC-157 is not FDA-approved; compounding permitted with a prescription (as of April 2026). Desmopressin is FDA-approved for one or more indications.
Read the full articles
- BPC-157 — full monograph: mechanism, research, dosing & references
- Desmopressin — full monograph: mechanism, research, dosing & references